Scolyer, Richard A.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 375

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 338

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 333

Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer

Akdemir, K. C., Le, V. T., Chandran, S., Li, Y., Verhaak, R. G., Beroukhim, R., Campbell, P. J., Chin, L., Dixon, J. R., Futreal, P. A., et al. (2020) · Nature Genetics

Genomics and Chromatin DynamicsChromatin Remodeling and Cancer

Cited by 283

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 256

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

Bauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N. A., Landi, M. T., Scolyer, R. A., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 211

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma

Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2007) · Modern Pathology

Cutaneous Melanoma Detection and ManagementCell death mechanisms and regulation

Cited by 202

Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors

Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 153

Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

Johansson, P. A., Brooks, K., Newell, F., Palmer, J. M., Wilmott, J. S., Pritchard, A. L., Broit, N., Wood, S., Carlino, M. S., Leonard, C., et al. (2020) · Nature Communications

Ocular Oncology and TreatmentsCancer Genomics and Diagnostics

Cited by 153

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., et al. (2019) · OncoImmunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 115

Recurrent inactivating RASA2 mutations in melanoma

Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J. S., Gartner, J. J., Di Pizio, A., Winograd-Katz, S., et al. (2015) · Nature Genetics

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 107

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma

Long, G. V., Shklovskaya, E., Satgunaseelan, L., Mao, Y., da Silva, I. P., Perry, K. A., Diefenbach, R. J., Gide, T. N., Shivalingam, B., Buckland, M. E., et al. (2025) · Nature Medicine

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 83

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Garg, M., Couturier, D.-L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G. B., Newton-Bishop, J., Parkinson, C., et al. (2021) · Nature Communications

Cutaneous Melanoma Detection and ManagementBreast Cancer Treatment Studies

Cited by 70

Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion

Boyd, S. C., Mijatov, B., Pupo, G. M., Tran, S. L., Gowrishankar, K., Shaw, H. M., Goding, C. R., Scolyer, R. A., Mann, G. J., Kefford, R. F., et al. (2013) · Journal of Investigative Dermatology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 53

Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells

Liu, Y. L., Lai, F., Wilmott, J. S., Yan, X. G., Liu, X. Y., Luan, Q., Guo, S. T., Jiang, C. C., Tseng, H.-Y., Scolyer, R. A., et al. (2014) · Oncotarget

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 40

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., et al. (2020) · Annals of Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 37

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients

Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 34

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene

van Kempen, L. C. L., Redpath, M., Elchebly, M., Klein, K. O., Papadakis, A. I., Wilmott, J. S., Scolyer, R. A., Edqvist, P.-H., Pontén, F., Schadendorf, D., et al. (2016) · Science Translational Medicine

Cutaneous Melanoma Detection and ManagementGenetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

Cited by 29

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Rozeman, E. A., Menzies, A. M., Krijgsman, O., Hoefsmit, E. P., van de Wiel, B. A., Sikorska, K., Van, T. M., Eriksson, H., Bierman, C., Gonzalez, M., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 20